1. An integrated circuit to control a process performed at a mobile station, the process comprising:
receiving information related to a set of sequences configured to be available in a cell for use by the mobile station, the information being broadcasted from a base station;
selecting a sequence from the set of sequences available in the cell; and
random-access-preamble-transmitting the selected sequence;
wherein the set of sequences available in the cell includes a sequence of r=a and a sequence of r=N\u2212a, where r is a sequence number, a is an integer, and N is a sequence length, and the allocated sequences are defined by the following equation or an equation cyclic shifted from the following equation:
c
r
\u2061
(
k
)
=
exp
\u2062
{
–
j
\u2062
2
\u2062
\u2062
\u03c0
\u2062
\u2062
r
N
\u2062
(
k
\u2061
(
k
+
1
)
2
+
qk
)
}
where k=0, 1, 2, . . . N\u22121, and q is an integer, and
the sequence of r=a and the sequence of r=N\u2212a are conjugate to each other.
2. The integrated circuit according to claim 1, comprising:
circuitry which, in operation, controls the process;
at least one input coupled to the circuitry, wherein the at least one input, in operation, inputs the information related to the set of sequences available in the cell; and
at least one output coupled to the circuitry, wherein the at least one output, in operation, outputs the selected sequence to be transmitted.
3. The integrated circuit according to claim 2, wherein the set of sequences available in the cell further includes a sequence of r=a\u2032 (a\u2032\u2260a) and a sequence of r=N\u2212a\u2032.
4. The integrated circuit according to claim 2, wherein the N is a prime number.
5. The integrated circuit according to claim 2, wherein the selecting includes randomly selecting the sequence from the set of sequences available in the cell.
6. The integrated circuit according to claim 2, wherein the set of sequences available in the cell is configured by a network that controls the base station.
7. The integrated circuit according to claim 2, wherein a number of the sequences configured to be included in the set of sequences available in the cell is less than the N.
8. The integrated circuit according to claim 2, wherein the information broadcasted from the base station includes an index indicative of the set of sequences available in the cell.
9. The integrated circuit according to claim 2, wherein the at least one output and the at least one input, in operation, are coupled to an antenna.
10. An integrated circuit comprising circuitry, which, in operation:
controls reception of information related to a set of sequences configured to be available in a cell for use by a mobile station, the information being broadcasted from a base station;
controls selection of a sequence from the set of sequences available in the cell; and
controls random-access-preamble-transmission of the selected sequence;
wherein the set of sequences available in the cell includes a sequence of r=a and a sequence of r=N\u2212a, where r is a sequence number, a is an integer, and N is a sequence length, and the allocated sequences are defined by the following equation or an equation cyclic shifted from the following equation:
c
r
\u2061
(
k
)
=
exp
\u2062
{
–
j
\u2062
2
\u2062
\u2062
\u03c0
\u2062
\u2062
r
N
\u2062
(
k
\u2061
(
k
+
1
)
2
+
qk
)
}
where k=0, 1, 2, . . . N\u22121, and q is an integer, and
the sequence of r=a and the sequence of r=N\u2212a are conjugate to each other.
11. The integrated circuit according to claim 10, further comprising:
at least one input coupled to the circuitry, wherein the at least one input, in operation, inputs the information related to the set of sequences available in the cell; and
at least one output coupled to the circuitry, wherein the at least one output, in operation, outputs the selected sequence to be transmitted.
12. The integrated circuit according to claim 11, wherein the set of sequences available in the cell further includes a sequence of r=a\u2032 (a\u2032\u2260a) and a sequence of r=N\u2212a\u2032.
13. The integrated circuit according to claim 11, wherein the N is a prime number.
14. The integrated circuit according to claim 11, wherein the selection includes randomly selecting the sequence from the set of sequences available in the cell.
15. The integrated circuit according to claim 11, wherein the set of sequences available in the cell is configured by a network that controls the base station.
16. The integrated circuit according to claim 11, wherein a number of the sequences configured to be included in the set of sequences available in the cell is less than the N.
17. The integrated circuit according to claim 11, wherein the information broadcasted from the base station includes an index indicative of the set of sequences available in the cell.
18. The integrated circuit according to claim 11, wherein the at least one output and the at least one input, in operation, are coupled to an antenna.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula I
wherein:
R1 is CO2R5 or CONR6R7;
R2 is cycloalkoxy or bridged 2.1.1, 2.2.1, 2.2.2, 3.1.1, or 3.2.1 bicycloalkoxy where the cycloalkyl or bridged bicycloalkyl moiety is substituted with 0-3 alkyl substituents;
or R2 is N(R8)(R9);
or R2 is pyrrolidinyl, piperidinyl, piperazinyl, N-alkylpiperazinyl, N-(BOC)piperazinyl, N-benzylmethylpiperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1 substituent selected from alkenyl, R11, (R11)alkyl, (R11CO)alkyl, pyrazinyl, pyrimidinyl, and phenyl where phenyl is substituted with 0-2 halo, alkyl, haloalkyl, cyano, hydroxy, alkoxy, haloalkoxy, CONH2, CONH(alkyl), or CON(alkyl)2 substituents;
or R2 is homopiperazinyl or diazepanone, and is substituted with 0-2 substituents selected from the group consisting of halo, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, pyrrolidinyl, piperidinyl, piperazinyl, N-(alkyl)piperazinyl, morpholinyl, thiomorpholinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyrimidinyloxy, phenyl substituted with 0-2 halo, alkyl, or alkoxy substituents, benzyl, (pyridinyl)methyl, benzyloxycarbonyl, alkylcarbonyl, alkoxycarbonyl, (R11)alkyl, and (R11CO)alkyl;
or R2 is
R3 is hydrogen, halo, alkyl, alkenyl, hydroxy, benzyloxy, or alkoxy;
R4 is C5-7cycloalkyl;
R5 is hydrogen or alkyl;
R6 is hydrogen, alkyl, cycloalkyl, alkoxy, or SO2R10;
R7 is hydrogen, alkyl, or cycloalkyl;
or NR6R7 taken together is pyrrolidinyl, piperidinyl, piperazinyl, N-(alkyl)piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl;
R8 is 4-piperidinyl, 4-(N-alkyl)piperidinyl, 3-(N-alkyl)pyrrolidinyl, (R11)alkyl, (R11CO)alkyl, (amino)cycloalkyl, (alkylamino)cycloalkyl, or (dialkylamino)cycloalkyl;
R9 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;
R10 is alkyl, haloalkyl, cycloalkyl, phenyl, amino, alkylamino, dialkylamino, benzylamino, or (benzyl)(alkyl)amino;
or R10 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo and alkyl; and
R11 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo and alkyl;
or a pharmaceutically acceptable salt thereof.
2. A compound of claim 1 where
R1 is CO2R5 or CONR6R7;
R2 is cycloalkoxy or bridged 2.1.1, 2.2.1, 2.2.2, 3.1.1, or 3.2.1 bicycloalkoxy, where the cycloalkyl or bridged bicycloalkyl moiety is substituted with 0-3 alkyl substituents;
or R2 is N(R8)(R9);
or R2 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1 substituent selected from R11, (R11)alkyl, (R11CO)alkyl, pyrazinyl, pyrimidinyl, pyrimidinyloxy, and phenyl where phenyl is substituted with 0-2 halo, alkyl or alkoxy substituents;
or R2 is homopiperazinyl or diazepanone, and is substituted with 0-2 substituents selected from the group consisting of halo, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, pyrrolidinyl, piperidinyl, piperazinyl, N-(alkyl)piperazinyl, morpholinyl, thiomorpholinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyrimidinyloxy, phenyl substituted with 0-2 halo, alkyl, or alkoxy substituents, benzyl, (pyridinyl)methyl, benzyloxycarbonyl, alkylcarbonyl, alkoxycarbonyl, (R11)alkyl, and (R11CO)alkyl;
or R2 is
R3 is hydrogen, halo, alkyl, alkenyl, hydroxy, benzyloxy, or alkoxy;
R4 is C5-7cycloalkyl;
R5 is hydrogen or alkyl;
R6 is hydrogen, alkyl, cycloalkyl, alkoxy, or SO2R10;
R7 is hydrogen, alkyl, or cycloalkyl;
or NR6R7 taken together is pyrrolidinyl, piperidinyl, piperazinyl, N-(alkyl)piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl;
R8 is 4-piperidinyl, 4-(N-alkyl)piperidinyl, (R11)alkyl, (R11CO)alkyl, (amino)cycloalkyl, (alkylamino)cycloalkyl, or (dialkylamino)cycloalkyl;
R9 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;
R10 is alkyl, haloalkyl, cycloalkyl, phenyl, amino, alkylamino, dialkylamino, benzylamino, or (benzyl)(alkyl)amino;
or R10 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo and alkyl; and
R11 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo and alkyl;
or a pharmaceutically acceptable salt thereof.
3. A compound of claim 1 where R is carboxy.
4. A compound of claim 1 where R1 is CONR6R7, R6 is SO2R10, and R7 is hydrogen.
5. A compound of claim 1 where R2 is NR8R9.
6. A compound of claim 1 where R2 is pyrrolidinyl, piperidinyl, piperazinyl, N-alkylpiperazinyl, N-(BOC)piperazinyl, N-benzylmethylpiperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1 substituent selected from alkenyl, R11, (R11)alkyl, (R11CO)alkyl, pyrazinyl, pyrimidinyl, and phenyl where phenyl is substituted with 0-2 halo, alkyl or alkoxy substituents.
7. A compound of claim 1 where R3 is hydrogen.
8. A compound of claim 1 where R3 is halo, alkyl, or alkoxy.
9. A compound of claim 1 where R4 is cyclohexyl.
10. A compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
11. A compound of claim 1 selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
12. A composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
13. The composition of claim 12 further comprising at least one additional compound having therapeutic benefits for HCV wherein the compound is selected from the group consisting of interferons, cyclosporins, interleukins, HCV metalloprotease inhibitors, HCV serine protease inhibitors, HCV polymerase inhibitors, HCV helicase inhibitors, HCV NS4B protein inhibitors, HCV entry inhibitors, HCV assembly inhibitors, HCV egress inhibitors, HCV NS5A protein inhibitors, HCV NS5B protein inhibitors, and HCV replicon inhibitors.
14. A method of treating hepatitis C infection comprising administering a therapeutically effective amount of a compound of claim 1 to a patient.
15. The method of claim 14 further comprising administering at least one additional compound having therapeutic benefits for HCV wherein the compound is selected from the group consisting of interferons, cyclosporins, interleukins, HCV metalloprotease inhibitors, HCV serine protease inhibitors, HCV polymerase inhibitors, HCV helicase inhibitors, HCV NS4B protein inhibitors, HCV entry inhibitors, HCV assembly inhibitors, HCV egress inhibitors, HCV NS5A protein inhibitors, HCV NS5B protein inhibitors, and HCV replicon inhibitors.